Epizyme Earns $10 Million from GSK for GLP Toxicology studies

Epizyme has earned a $10 million milestone payment from GlaxoSmithKline (GSK) to follow GSK’s initiation of GLP toxicology studies for a first-in-class methyltransferase inhibitor discovered by Epizyme and licensed to GSK.

Epizyme Chief Business Susan Graf Officer that they are pleased to achieve another milestone under their collaboration with GSK, further validating the strength of their epigenetic approach and drug discovery platform, as well our success in collaborating with industry leaders like GSK. They are encouraged that this investigational medicine continues to advance toward the clinic.